All News

2019

March

A look inside a tumor
Story / Mar 19, 2019

Visualizing immuno-oncology research

Learn how Novartis researchers are working to outsmart tumors.

Read More

January

Media Release / Jan 30, 2019

Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018

Read More
Media Release / Jan 08, 2019

Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Read More
2018

December

Media Release / Dec 21, 2018

Novartis successfully completes acquisition of Endocyte

Read More
Media Release / Dec 21, 2018

Novartis receives European Commission (EC) approval for expanded indication for Kisqali® (ribociclib)

Read More
Media Release / Dec 20, 2018

Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies

Read More
Media Release / Dec 20, 2018

Novartis announces new CEO of Oncology Business Unit

Read More
President of Advanced Accelerator Applications shares her story for “Women in Science.”
Story / Dec 12, 2018

Women in Science: Susanne Schaffert

Susanne Schaffert, President of Advanced Accelerator Applications, describes her career in science.

Read More
Story / Dec 10, 2018

The changing landscape of cancer treatment

Read More
Media Release / Dec 08, 2018

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More